Understand the source comparison
Peptides for Repetitive Strain Injury Protocol Evidence Guide: Comparison
BPC-157 VEGF upregulation, fibroblast migration, angiogenesis at injury sites 250–500mcg subcutaneously twice daily for 6–8 weeks Initial pain reduction 7–14 days, structural improvement 4–6 weeks Preclinical only. Multiple animal tendon studies show accelerat
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- VEGF upregulation, fibroblast migration, angiogenesis at injury sites
- 250–500mcg subcutaneously twice daily for 6–8 weeks
- Initial pain reduction 7–14 days, structural improvement 4–6 weeks
- Preclinical only. Multiple animal tendon studies show accelerated healing
- Strongest mechanistic evidence for tendon repair, but no human RCTs. Use limited to research protocols
- TB-500
- Actin binding, cell migration promotion, satellite cell activation
- 2–5mg subcutaneously twice weekly (loading), then 2mg weekly (maintenance) for total 8 weeks
- Tissue remodeling effects visible 3–4 weeks, peak benefits 6–8 weeks
- Preclinical cardiac and muscle studies, no tendon-specific human trials
- Complements BPC-157 for late-stage remodeling, longer half-life allows less frequent dosing
- GHK-Cu (Copper Peptide)
- Collagen synthesis stimulation, anti-inflammatory cytokine modulation
- 1–2mg subcutaneously daily or topical application at injury site
- Cosmetic effects (skin) appear 2–4 weeks, deeper tissue effects unclear
- Limited preclinical wound healing data, primarily studied for skin applications
- Weaker evidence base for deep tendon injury. Most data from dermal wound models
- Ipamorelin + CJC-1295
- Growth hormone secretagogue. Indirect tissue repair through systemic GH elevation
- 200–300mcg each peptide subcutaneously before bed, 5 days/week for 12+ weeks
- Systemic effects (sleep, recovery) 2–4 weeks, localized injury benefits uncertain
- Human studies exist for GH secretion, extrapolated benefits for tissue repair not directly studied
- Addresses systemic recovery environment but not localized tendon pathology. Best as adjunct, not primary intervention